News Meet Dalton, a new AI-powered drug discovery platform Just a few months after emerging from stealth, the UK's DaltonTx has launched its AI in drug discovery platform and revealed its first client.
News EULAR 26 hears of treatment advances in lupus Three trials of potentially first-in-class therapies for J&J, UCB/Biogen, and Merck KGaA at EULAR have offered hope of new targeted drugs for lupus.
News £600m funding call opens for UK biomedical research centres £600m in funding is being allocated for an expansion in the network of biomedical research centres, a pillar of the UK's life sciences strategy.
News NewLimit raises $435m for liver trials, and other financings Longevity biotech NewLimit's $435m Series C heads this week's round-up of biotech venture capital financings.
News AbbVie's ovarian cancer drug Elahere gets NHS green light AbbVie's Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, providing an alternative to chemotherapy.
News Lilly strikes $1.9bn kidney disease alliance with Ascidian In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.